Amgen to Unveil Full Phase 2 MariTide Data and Cardiometabolic Research Highlights at ADA 2025 Scientific Sessions
Amgen has announced that it will present comprehensive data from Part 1 of its Phase 2 clinical study for MariTide (maridebart cafraglutide), formerly known as AMG 133, at the upcoming 85th Scientific Sessions of the American Diabetes Association (ADA), set to take place from June 20 to 23, 2025, in Chicago. The presentations will also include new insights from Amgen’s Phase 3 FOURIER study of Repatha® (evolocumab) and the VESALIUS-REAL study exploring real-world lipid management practices.
The ADA’s annual meeting is one of the most influential forums for showcasing scientific and clinical advancements in diabetes and metabolic disease research. Amgen’s participation reflects its strategic focus on cardiometabolic disorders, a therapeutic area the company is rapidly expanding through innovative candidates like MariTide.
Spotlight on MariTide: A Novel Approach to Chronic Weight Management
A centerpiece of Amgen’s ADA 2025 program is the full results from Part 1 of its Phase 2 clinical trial evaluating MariTide, a once-monthly (or less frequently) administered long-acting peptide-antibody conjugate designed to support chronic weight management in individuals living with obesity, both with and without Type 2 diabetes.
MariTide represents a new generation of obesity therapeutics. Unlike traditional peptide-only approaches, its antibody-based design may enhance durability, extend dosing intervals, and potentially reduce tolerability-related treatment discontinuations. The therapy is administered via subcutaneous injection and is being studied for its ability to produce and sustain significant weight loss over extended periods.
These new 52-week data will be unveiled during a dedicated symposium scheduled for Monday, June 23, from 1:30 p.m. to 3:00 p.m. CDT. The session, led by expert endocrinologists and obesity researchers, will provide a detailed look at efficacy, safety, and tolerability metrics for MariTide over the course of one year. It will also include full findings from the Phase 1 PK-LDI (pharmacokinetics low dose initiation) study and updates on the upcoming Phase 3 MARITIME studies, which will evaluate MariTide across broader populations and settings.
Amgen previously shared topline results from the Phase 2 trial in November 2024, indicating promising weight loss outcomes and an absence of plateauing—a common challenge seen with some other weight loss therapies. At ADA 2025, the company aims to deepen the clinical narrative by sharing more comprehensive and peer-reviewed data.
A Word from Amgen’s R&D Leadership
Dr. Jay Bradner, executive vice president of Research and Development at Amgen, emphasized the significance of the forthcoming data presentation, stating:
“We look forward to sharing results from our cardiometabolic research at the upcoming ADA meeting, which include 52-week data from Part 1 of the Phase 2 MariTide study showing robust weight loss without a weight loss plateau in people living with obesity, with and without Type 2 diabetes.”
He added that the data have played a crucial role in shaping the Phase 3 MARITIME development program, which is designed to further evaluate the long-term effectiveness and clinical differentiation of MariTide.
Amgen believes that MariTide could emerge as a unique and highly differentiated option in a competitive obesity treatment landscape, potentially offering better patient adherence and sustained outcomes compared to currently available therapies.
Repatha and VESALIUS-REAL: Cardiovascular Data Also on the Agenda
While MariTide is the highlight, Amgen’s ADA presence extends to cardiovascular care and lipid management—a reflection of the interconnected nature of metabolic and cardiovascular diseases.
Key presentations will include:
- Phase 3 FOURIER Study on Repatha® (evolocumab): This pivotal study evaluates the long-term cardiovascular benefits of Repatha, a PCSK9 inhibitor, in patients at risk for cardiovascular events. New data will delve deeper into its impact across diverse patient subgroups.
- VESALIUS-REAL Study: This real-world analysis investigates lipid management patterns in clinical practice, offering insights into how patients are being treated outside of controlled clinical trial settings. The findings are expected to inform healthcare systems and providers about adherence gaps and optimization strategies in statin and non-statin therapy use.
These studies reflect Amgen’s integrated approach to managing cardiometabolic disease—a therapeutic area that increasingly requires coordinated solutions across obesity, diabetes, and cardiovascular risk.
Investor Webcast to Follow Key Presentations
To coincide with the ADA presentations, Amgen will host a live webcast call for the investment community on Monday, June 23 at 4:30 p.m. CDT. Dr. Bradner and other members of Amgen’s leadership team will walk through key data readouts, particularly focusing on MariTide and its implications for Amgen’s strategic direction in obesity and metabolic care.
The webcast will be accessible through Amgen’s Investor Relations portal at www.amgen.com and will remain archived for at least 90 days following the event.
This investor briefing provides an opportunity for analysts and shareholders to gauge the commercial potential of MariTide in light of the growing obesity market, especially with competitors such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound showing strong performance.
ADA 2025 Booth Experience: A Multisensory Obesity Awareness Campaign
In addition to formal presentations, Amgen will also engage ADA attendees through a dynamic, interactive booth (#1338) in the Exhibit Hall. This year’s offering includes:
- ADA Interactive Obesity Experience: An immersive video installation designed to help healthcare professionals and attendees understand the physical, psychological, and societal challenges faced by people living with obesity.
- Word Cloud Activation: Visitors can contribute to a collaborative art and awareness project that reflects shared perspectives on living with or treating obesity. This initiative seeks to spark dialogue around stigma, patient journeys, and evolving standards of care.
Through this experience, Amgen aims to foster a deeper understanding of obesity as a chronic, relapsing, and multi-factorial disease—requiring not just new therapies but also new narratives.
A Defining Moment for MariTide and Amgen’s Obesity Strategy
Amgen’s presence at the 2025 ADA Scientific Sessions marks a major milestone in the company’s expanding focus on metabolic and cardiovascular diseases. The full 52-week data from the Phase 2 MariTide trial could establish the investigational therapy as a serious contender in the high-growth obesity market.
With promising early results, a well-designed Phase 3 program underway, and a vision for long-acting, low-frequency treatments, Amgen is positioning MariTide not just as another GLP-1 alternative—but as a potentially transformative therapy with unique attributes that could benefit a wide range of patients.
At the same time, the company’s focus on Repatha and real-world lipid management highlights its commitment to addressing cardiometabolic risk holistically. Whether in scientific sessions, investor calls, or booth experiences, Amgen is making it clear that it intends to be a major player in reshaping the landscape of obesity and related chronic diseases.
